Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

University Hospital, Clermont-Ferrand30 enrolled

Overview

determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days). Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Benign Disease

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 0 to 18 years * allogeneic bone marrow transplantation for malignant or benign disease * affiliation to French sécurité sociale * parent's consent Exclusion Criteria: * severe gastro-intestinal involvement before transplant * previous digestive surgery

Locations (1)

Etienne MERLIN

Clermont-Ferrand, France

RECRUITING

Outcomes

Primary Outcomes

Citrullinemia (weekly)

Time frame: weekly

Secondary Outcomes

Gastro-intestinal complications in children following allogeneic bone marrow transplantation

Time frame: following allogenic bone marrow transplantation

Central Contacts

Lacarin Patrick

CONTACT

placarin@chu-clermontferrand.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.